CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma.
Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究表明,异位 CXCR2 在提高 CAR-T 疗法针对原发性和转移性 PDAC 的效率方面发挥了重要且有前景的作用,并部分逆转了免疫抑制微环境。
CAR-T 细胞疗法治疗胰腺导管腺癌(PDAC)的最新进展仍令人失望,部分归因于免疫抑制微环境,包括巨噬细胞介导的T细胞耗竭。
我们首先表征了巨噬细胞相关趋化因子的表达模式,并确定CXCR2是调节PDAC微环境中T细胞运输和肿瘤特异性聚集的关键因子。之后,我们合成并将CXCR2表达级联引入Claudin18.2 CAR-T 细胞,并比较了CAR-T 细胞在体外和体内的行为。CXCR2 CAR-T 的治疗潜力在两种不同的同种异体模型中进行了评估:皮下同种移植瘤和转移性PDAC模型。
结果显示,CXCR2 CAR-T 不仅缩小了同种移植PDAC肿瘤的体积,还完全消除了转移灶的形成。最后,我们对肿瘤组织进行了研究,发现异位CXCR2的表达显著改善了T细胞对肿瘤的靶向浸润和驻留,并减少了PDAC微环境中MDSCs和CXCR2+巨噬细胞的存在。
Recent progressions in CAR-T cell therapy against pancreatic ductal adenocarcinoma (PDAC) remain disappointing, which are partially attributed to the immunosuppressive microenvironment including macrophage-mediated T cell repletion.
We first characterized the expression patterns of macrophage-relevant chemokines and identified CXCR2 as the key factor regulating T cell trafficking and tumor-specific accumulation in PDAC microenvironment. After that, we synthesized and introduced a CXCR2 expression cascade into Claudin18.2 CAR-T cells and compared the behaviors of CAR-T cells in vitro and in vivo. The therapeutic potential of CXCR2 CAR-T was evaluated in two different allogeneic models: subcutaneous allografts and metastatic PDAC models.
The results showed that CXCR2 CAR-T not only reduced the size of allografted PDAC tumors, but also completely eliminated the formation of metastases. Lastly, we investigated the tumor tissues and found that expression of ectopic CXCR2 significantly improved tumor-targeted infiltration and residence of T cells and reduced the presence of MDSCs and CXCR2 + macrophages in PDAC microenvironment.
Our studies suggested that ectopic CXCR2 played a significant and promising role in improving the efficiency of CAR-T therapy against primary and metastatic PDAC and partially reversed the immune-suppressive microenvironment.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。